Provided by Tiger Fintech (Singapore) Pte. Ltd.

BioCardia

1.75
-0.1730-9.01%
Post-market: 1.800.0530+3.03%17:18 EDT
Volume:38.70K
Turnover:70.50K
Market Cap:8.18M
PE:-0.60
High:1.94
Open:1.94
Low:1.75
Close:1.92
Loading ...

BRIEF-Biocardia Announces Positive Dsmb Review Of Cardiallo Allogeneic Cell Therapy For Heart Failure Phase 1/2 Clinical Trial

Reuters
·
15 Apr

BioCardia’s CardiALLO Trial Advances After Safety Review

TIPRANKS
·
15 Apr

BioCardia Announces Positive Dsmb Review of Cardiallo Allogeneic Cell Therapy for Heart Failure Phase 1/2 Clinical Trial

THOMSON REUTERS
·
15 Apr

BioCardia Inc: Plans to Progress Trial to Enrollment of 39 Participants in United States

THOMSON REUTERS
·
15 Apr

BioCardia Announces Positive DSMB Review of CardiALLO Allogeneic Cell Therapy for Heart Failure Phase 1/2 Clinical Trial

GlobeNewswire
·
15 Apr

BioCardia Says Emory University Enrolling Heart Patients for CardiAMP HF II Trial

MT Newswires Live
·
12 Apr

BRIEF-Biocardia Initiates Patient Enrollment At Emory University School Of Medicine

Reuters
·
11 Apr

BioCardia Initiates Patient Enrollment at Emory University School of Medicine for Ongoing Cardiamp HF Ii Pivotal Study

THOMSON REUTERS
·
11 Apr

BioCardia Initiates Patient Enrollment at Emory University School of Medicine for Ongoing CardiAMP HF II Pivotal Study

GlobeNewswire
·
11 Apr

BioCardia’s Earnings Call Highlights Strong Trial Results

TIPRANKS
·
02 Apr

BioCardia Inc (BCDA) Q4 2024 Earnings Call Highlights: Strategic Cost Reductions and Promising ...

GuruFocus.com
·
01 Apr

BioCardia Clarifies Timing for CardiAMP-HF Results Call

TIPRANKS
·
01 Apr

BioCardia’s Conference Call Today, Monday, March 31, 2025 to be Held at 4:30PM EDT Time Today

GlobeNewswire
·
01 Apr

BioCardia's Ischemic HF Cell Therapy Trial Reached no 'Statistical Significance' in Primary Composite Efficacy Endpoint

MT Newswires Live
·
31 Mar

BioCardia Phase 3 Cardiamp-HF Trial of Novel Cardiac Cell Therapy for Ischemic Heart Failure Shows Increased Survival, Decreased Cardiac Events, and Improved Quality of Life at Two Years

THOMSON REUTERS
·
31 Mar

Biocardia Phase 3 CardiAMP-HF Trial of Novel Cardiac Cell Therapy for Ischemic Heart Failure Shows Increased Survival, Decreased Cardiac Events, and Improved Quality of Life at Two Years

GlobeNewswire
·
31 Mar

BioCardia Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St.
·
28 Mar

BioCardia Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
27 Mar

BioCardia FY 2024 GAAP EPS $(2.90) Beats $(3.11) Estimate, Sales $58.00K Miss $91.50K Estimate

Benzinga
·
27 Mar

BioCardia Reports 2024 Business Highlights and Financial Results

THOMSON REUTERS
·
27 Mar